OncoMethylome to Develop Biomarkers for GSK Biologicals' Cancer Rx | GenomeWeb
NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today it will develop DNA methylation biomarkers for GlaxoSmithKline Biologicals that the drugmaker will use in its cancer immunotherapy program. 
The Belgian company will test its portfolio of methylation markers on clinical samples from GSK Biologicals, said OncoMethylome’s CTO, Jim DiGuiseppi.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.